Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Ed Arce reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and maintains $4.5 price ...
Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate...
Benchmark analyst Bruce Jackson reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative Buy and maintains $3 pric...
Piper Sandler analyst Yasmeen Rahimi initiates coverage on Unicycive Therapeutics (NASDAQ:UNCY) with a Overweight rating and...
Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate...
HC Wainwright & Co. analyst Ed Arce reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and maintains $4.5 price ...
Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarte...
